Seminar title “From EBOLA to COVID-19: DMPK steps along the journey of Remdesivir”
Wednesday, March 3, from 3:30 – 3:40 via WebEX : https://uconn-cmr.webex.com/join/boc07001
Dr. Lai is a Senior Director of Drug Metabolism in Gilead Sciences.
Dr. Lai has more than 20 years in research and 17+ years of drug development experience, obtained at 3 international pharma/biopharma companies, encompassing research in transporter-related ADME-PK-Tox; Experienced department leader in developing scientific-strategic plans to translate ADME-PK/PD from pre-clinical to human; Highly proficient at leveraging non-clinical data and information combined with PK/PD and PBPK modeling & simulation approaches to anticipate and predict properties in human; Dedicated in discovering and developing new medicines for patients across multiple therapeutic areas including oncology, inflammation, cardiovascular, anti-infectives and metabolic liver diseases; Known for building cultures of trust, collaboration and courage to deliver results through ratiocination. Associate editor/editorial board members of top ranking DMPK journals: DMD, BDD, JPS and Frontier Pharmacology etc. The author of a book, book chapters and over 160 original publications.
For more information, contact: Xiaobo Zhong at 860-486-3697